Altitude Trampoline Park Names Chris Kuehn as Chief Operating Officer
Premier Family-Friendly Entertainment Destination is Expanding its Leadership Team to Boost Franchise Operations and Drive Marketing and Training Advancements
"Chris brings a wealth of general management expertise that will be crucial for Altitude's innovations and development," said
Kuehn most recently led business development teams for software provider Restaurant365 partnering with Enterprise Brands delivering Operations and Financial technology platform solutions that drive efficiency and profitability. Prior to R365, Kuehn held senior level positions in operations and marketing at PepsiCo, Yum Brands, Arby's, and Golden Corral. The latter two brands he held the position of Senior Vice President and Chief Marketing Officer for a total of 16 years, driving innovation in multiple disciplines including marketing, purchasing and real estate development.
"Building upon the brand's operational success in 2023, I am eager to dive into this position at Altitude with the support of a strong and fast-growing parent company full of experts in the family entertainment industry," said Kuehn.
The brand is actively seeking qualified candidates to help grow its footprint throughout the
About
About Indoor Active Brands
Indoor Active Brands is a platform company focused on owning and operating franchising concepts in the indoor family entertainment industry. Created by NRD Capital, Indoor Active Brands currently consists of
Media Contact:
[email protected] | 956-893-9150
View original content to download multimedia:https://www.prnewswire.com/news-releases/altitude-trampoline-park-names-chris-kuehn-as-chief-operating-officer-302173766.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
- NICE Supports Routine NHS Funding and Access to Ex-Situ Machine Perfusion in a Major Step Forward for Liver Transplantation
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share